Xintela AB (OSTO:XINT) Short Percentage of Float


OSTO:XINT Xintela AB OSTO:XINT
8 GF Score
Price kr0.20
! 2 Warning Signs
View Full Analysis

What is Xintela AB Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

OSTO:XINT vs VRTX, REGN, ALNY: Short Percentage of Float Comparison

For the Biotechnology subindustry, Xintela AB's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Xintela AB Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xintela AB's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Xintela AB's Short Percentage of Float falls into.


OSTO:XINT
8GF Score
Xintela AB OSTO:XINT
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xintela AB Business Description

Other Exchanges 1XT:Germany
Address Medicon Village, Lund, SWE, 223 81
Xintela AB is a clinical-stage biopharmaceutical company that develops cutting-edge medical products in stem cell therapy and targeted cancer therapy. Its wholly owned subsidiary, Targinta AB, develops First-in-Class therapeutic antibodies targeting integrin ?10?1. TARG9, an antibody-drug conjugate (ADC), and TARG10, a function-blocking antibody, are in preclinical development for the treatment of aggressive, difficult-to-treat cancers, including triple-negative breast cancer and brain tumor glioblastoma. Xintela has two clinical studies ongoing with the stem cell product XSTEM and EQSTEM.
8GF Score

Get the complete analysis for OSTO:XINT

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.20
Price